Growth Suppression of Human Head and Neck Cancer Cells by the Introduction of a Wild-Type p53 Gene via a Recombinant Adenovirus

Ta-Jen Liu, Wei-Wei Zhang, Dorothy L. Taylor, Jack A. Roth, Helmuth Goepfert, and Gary L. Clayman

Abstract

Mutations of the p53 gene constitute one of the most frequent genetic alterations in squamous cell carcinoma of the head and neck (SCCHN). In this study, we introduced wild-type p53 into two separate SCCHN cell lines via a recombinant adenoviral vector, Ad5CMV-p53. Northern blotting showed that following infection by the wild-type p53 adenovirus (Ad5CMV-p53), cells produced up to 10-fold higher levels of exogenous p53 mRNA than cells treated with vector only (without p53). Western blotting showed that the increased levels of p53 protein produced in the Ad5CMV-p53-infected cells were a reflection of p53 mRNA expression. In vitro growth assays revealed growth arrest following Ad5CMV-p53 infection as well as cell morphological changes consistent with apoptosis. In vivo studies in nude mice with established s.c. squamous carcinoma nodules showed that tumor volumes were significantly reduced in mice that received peritumoral infiltration of Ad5CMV-p53. These data suggest that Ad5CMV-p53 may be further developed as a potential novel therapeutic agent for SCCHN since introduction of wild-type p53 into SCCHN cell lines attenuates their replication and tumor growth.

Introduction

Patients with SCCHN are afflicted with a disease process that often has profound effects on speech, swallowing, and cosmesis. Furthermore, the overall rate of survival among these patients has remained unchanged at approximately 45% for nearly 30 years since contemporary surgery and radiation therapy were instituted (1). Treatment failures among these patients remain local and regional; only 10–15% of patients with the disease die of distant metastasis alone (2).

Although we have gained in understanding of the molecular events in the initiation and progression of SCCHN, they continue to require intensive investigation. A recent study identifying loss of heterozygosity of chromosome 9p21–22 as the most frequent genetic alteration in SCCHN suggested that this may be an early event in progression toward this neoplasm (3). Additionally, amplification and/or overexpression of cellular and nuclear oncopgenes, such as c-erbB-1 (4), int-2 (5), bcl-2 (6) and c-myc (7), have been documented in these cancers. The tumor suppressor gene p53 has been the subject of immense interest and investigation in recent years. Alterations in the p53 gene, including deletion, insertion, and point mutation, are the most frequent genetic events in many different carcinomas, such as those of the colon (8), breast (9), and lung (10), as well as soft-tissue sarcomas and leukemias (11). Several investigators have demonstrated the high frequency of p53 gene alterations in SCCHN (12, 13).

There is considerable evidence implicating mutations of the p53 gene in the etiology of many human cancers (14). Reports have demonstrated that growth of several different human cancer cell lines, including representatives of colon cancer (15), glioblastoma (16), breast cancer (17), and osteosarcoma (18), can be functionally suppressed by DNA transfection or retrovirus-mediated transfer of the wild-type p53 gene. This gene may have an important role not only in cell growth but in apoptosis (programmed cell death). Induction of exogenous expression of wild-type p53 has been shown to induce apoptosis in colon cancer cell lines (19) and in human lung cancer spheroids (20).

The adenoviral vector has emerged as a leading candidate for in vivo gene therapy in the past few years. It enjoys an advantage over traditional DNA transfection and retroviral transfer in its high efficiency of transferring potentially therapeutic genes into a wide range of host cells (21). The recently created adenoviral vector containing wild-type p53 (Ad5CMV-p53; Ref. 22) provides us with an attractive delivery system to investigate the effect of exogenous wild-type p53 on SCCHN cell lines both in vitro and in vivo. The outcome of this study indicates that further development of the p53 adenovirus or other novel molecular therapies for SCCHN is warranted.

Materials and Methods

Cell Lines and Culture Conditions. Human SCCHN cell lines Tu-138 and Tu-177 were both established at the Department of Head and Neck Surgery, M. D. Anderson Cancer Center. Tu-138 and Tu-177 were established from a gingivo-labial moderately differentiated squamous carcinoma and a poorly differentiated squamous carcinoma of the larynx, respectively. Both cell lines were developed via primary explant technique and are cytokeratin positive and tumorigenic in athymic nude and SCID mice. These cells were grown in DMEM/F12 medium supplemented with 10% heat-inactivated FBS with penicillin/streptomycin.

Recombinant Adenovirus Preparation and Infection. The recombinant p53 adenovirus (Ad5CMV-p53; Ref. 22) contains the CMV promoter, wild-type p53 cDNA, and SV40 polyadenylation signal in a minigene cassette inserted into the E1-deleted region of modified Ad5. Viral stocks were propagated in 293 cells. Cells were harvested 36–40 h after infection, pelleted, resuspended in phosphate-buffered saline, and lysed; cell debris was removed by subjecting the cells to CsCl gradient purification. Concentrated virus was dialyzed, aliquoted, and stored at −80°C. Infection was carried out by the addition of the virus to the DMEM/F12 medium and 2% FBS to the cell monolayers. The cells were incubated at 37°C for 60 min with constant agitation. Then complete medium (DMEM/F12–10% FBS) was added, and the cells were incubated at 37°C for the desired length of time.

Northern Blot Analysis. Total RNA was isolated by the acid-guanidinium thiocyanate method of Chomczynski and Sacchi (23). Northern analyses were performed on 20 μg of total RNA. The membrane was hybridized with a p53 probe forming units.

Received 4/18/94; accepted 6/2/94.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by: American Cancer Society Career Development Award 93-9 (to G. L. C.); M. D. Anderson Cancer Center Core Grant NIH-NCI-CA09611 (both to J. A. R.); by gifts to the Division of Surgery from Tenneco and Exxon for the Core Lab Facility; the University of Texas M. D. Anderson Cancer Center Core Grant CA16672; Grant RO1 CA-45187 from the National Cancer Institute and Training Grant CA09611 (both to J. A. R.); by gifts to the Division of Surgery from Tenneco and Exxon for the Core Lab Facility; the University of Texas M. D. Anderson Cancer Center Core Grant CA16672; and by a generous gift from the Mathers Foundation.

2 To whom requests for reprints should be addressed, at M. D. Anderson Cancer Center, Department of Head and Neck Surgery, Box 69, 1515 Holcombe Boulevard, Houston, TX 77030.

3 The abbreviations used are: SCCHN, squamous cell carcinoma of the head and neck; DMEM/F12, Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium; FBS, fetal bovine serum; AdS, adenovirus 5; CMV, cytomegalovirus; Ad5CMV-p53, wild-type p53 adenovirus; cDNA, complementary DNA; MOI, multiplicity of infection; SDS, sodium dodecyl sulfate; β-gal, β-galactosidase; d1312, replication-defective adenovirus; PFU, plaque forming units.
cDNA probe labeled by the random primer method in 5 × SSC-5 × Denhardt’s solution-0.5% SDS-denatured salmon sperm DNA (20 µg/ml).

The membrane was also stripped and reprobed with glyceraldehyde-3-phosphate dehydrogenase cDNA for RNA loading control. The relative quantities of p53 expressed were determined by densitometer (Molecular Dynamics, Inc., Sunnyvale, CA).

**Western Blot Analysis.** Total cell lysates were prepared by sonication of the cells 24-h postinfection in RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0) for 5 s. Fifty µg of protein from samples were subjected to 10% SDS-polyacrylamide gel electrophoresis and transferred to Hybond-ECL membrane (Amersham). The membrane was blocked with BLOTTO/Tween (5% nonfat dry milk, 0.2% Tween 20, and 0.02% sodium azide in phosphate-buffered saline) and probed with the primary antibodies, mouse anti-human p53 monoclonal antibody PAb1801 and mouse anti-human β-actin monoclonal antibody (Amersham), and the secondary antibody, horseradish peroxidase-conjugated goat anti-mouse IgG (Boehringer Mannheim, Indianapolis, IN). The membrane was processed and developed as the manufacturer suggested.

**Immunohistochemical Analysis.** The infected cell monolayers were fixed with 3.8% formalin and treated with 3% H2O2 in methanol for 5 min. Immunohistochemical staining was performed by using the Vectastain Elite kit (Vector, Burlingame, CA). The primary antibody used was the anti-p53 antibody PAb1801, and the secondary antibody was an avidin-labeled anti-mouse IgG (Vector). The biotinylated horseradish peroxidase avidin-biotin complex reagent was used to detect the antigen-antibody complex. Preadsorption controls were used in each immunostaining experiment. The cells were then counterstained with Harris hematoxylin (Sigma Chemical Co., St. Louis, MO).

**Cell Growth Assay.** Cells were plated at a density of 2 × 10^6 cells/ml in 6-well plates in triplicate. Cells were infected with either wild-type (Ad5CMV-p53) or replication-defective adenovirus as a control. Cells were harvested every 2 days and counted; their viability was determined by trypan blue exclusion.

**Inhibition of Tumor Growth in Vivo.** The effect of Ad5CMV-p53 on established s.c. tumor nodules was determined in nude mice in a defined pathogen-free environment. Experiments were reviewed and approved by institutional committees for both animal care and use and for recombinant DNA research. Briefly, following induction of acepromazine/ketamine anesthesia, three separate s.c. flaps were elevated on each animal, and 5 × 10^6 cells 150 µl of complete media were injected s.c. into each flap using a blunt needle; the cells were kept in the pocket with a horizontal mattress suture. Four animals were used for each cell line. After 4 days, the animals were reanesthetized, and the flaps were reelevated for the delivery of 100 µl of: (a) Ad5CMV-p53 (10^6 PFU) in the right anterior flap; (b) replication-defective virus (10^6 PFU) in the right posterior flap; and (c) transport medium alone, in the left posterior flank. All injection sites had developed s.c. visual and palpable nodules. Experiments were reviewed and approved by institutional committees for both animal care and use and for recombinant DNA research. Following sacrifice, excised tumors were measured three dimensionally by microcalipers to determine tumor volume. A nonparametric Friedman’s two-way analysis of variance test was used to test the significance of the differences between means of samples; the SPSS/PC+ software package (SPSS, Inc., Chicago, IL) was used.

**Results**

**Adenoviral Infection of SCCHN Cells.** The conditions for optimal adenoviral transduction of Tu-138 and Tu-177 cells were determined by infecting these cells with adenovirus expressing the *Escherichia coli* β-gal gene. The transduction efficiency was assessed by counting the number of blue cells after β-galactosidase expression. There appeared to be a linear relationship between the number of infected cells and the number of adenovirus particles used. Cells inoculated with a single dose of 100 MOI β-gal adenovirus exhibited 60% blue cells (Fig. 1A), and this was improved to 100% by multiple infections (data not shown). The transduction efficiency of this vector in SCCHN cells is quite different from that of other cell lines examined previously; HeLa, HepG2, LM2, and human non-small cell lung cancer cell lines showed 97 to 100% infection efficiencies after incubation with 30 to 50 MOI β-gal adenovirus (22).

**Expression of Exogenous p53 mRNA in Adenovirus-infected SCCHN Cells.** Two human SCCHN cell lines were chosen for this study; both cell lines Tu-138 and Tu-177 possess a mutated p53 gene (unpublished data). The recently created recombinant wild-type p53 adenovirus, Ad5CMV-p53, was used to infect Tu-138 and Tu-177 cells. Twenty-four h after infection, total RNA was isolated, and Northern blot analysis was performed. The transformed primary human embryonal kidney cell line 293 was used as a positive control because of its high level of expression of the p53 gene product, whereas K562, a lymphoblastoma cell line with a homozygous deletion of the p53 gene, was the negative control (Fig. 1B, Lanes 1 and 2, respectively). Due to unequal loading, only a fraction of the endogenous p53 mRNA was detected in the 293 cells (Fig. 1B, bottom panel). The levels of the 2.8-kilobase endogenous p53 mRNA detected in the samples isolated from mock-infected cells (Fig. 1B, Lanes 3 and 6) and from the cells infected with a replication-defective adenovirus, dl312 (Fig. 1B, Lanes 4 and 7), were similar. Up to 10-fold higher levels of exogenous 1.9-kilobase p53 mRNA were present in the cells infected with Ad5CMV-p53 (Fig. 1B, Lanes 5 and 8), indicating that the exogenous p53 cDNA was successfully transduced into these cells and efficiently transcribed. Interestingly, the levels of endogenous p53 mRNA in these cells was 5-fold higher than in the experimental controls. Northern blots exhibited no evidence of Ad5CMV-p53 (DNA) contamination of RNA.
Expression of p53 Protein in Adenovirus-infected SCCHN Cells. Western blot analysis was performed to compare the levels of p53 mRNA to the amount of p53 protein produced. A p53 band, recognized by monospecific anti-p53 antibody, PAb1801, was observed in cellular extracts isolated from all samples except K562 cells (Fig. 2A, Lane 8). Cell line 293 showed high levels of p53 protein (Fig. 2A, Lane 1). Samples isolated from mock-infected Tu-138 and Tu-177 cells exhibited low levels of p53 protein (Fig. 2A, Lanes 2 and 5). The level of p53 expression remained similar in those cells infected with the dl312 adenovirus (Fig. 2A, Lanes 3 and 6). The levels of p53 antigen detected in AdSCMV-p53-infected cells were significantly higher than the levels of the endogenous mutated proteins in both cell lines (Fig. 2A, Lanes 5 and 7). This result indicates that the exogenous p53 mRNA produced from cells infected with Ad5CMV-p53 is efficiently translated into immunoreactive p53 protein. Furthermore, immunohistochemical analysis of cells infected with Ad5CMV-p53 revealed the characteristic nuclear staining of p53 protein (Fig. 2B, right panel), whereas mock-infected cells failed to show similar staining despite the presence of the p53 protein in these cells (Fig. 2B, left panel). This inability to detect the protein may be attributable to the insensitivity of the assay.

Effect of Exogenous p53 on SCCHN Cell Growth in Vitro. Cells infected with control virus dl312 had growth rates similar to those of the mock-infected cells (Fig. 3), whereas growth of the Ad5CMV-

![Western blot analysis](image1)

![Immunohistochemical staining](image2)
effects. Fig. 4 shows representative Tu-138 (left) and Tu-177 recipients (right). Sizable tumors are apparent on both posterior flaps of the animals (i.e., the sites that did not receive Ad5CMV-p53). The lack of tumor progression is significant in the right anterior flaps of the animals which received Ad5CMV-p53 ($P < .04$). That Tu-177 cells have a slower growth rate has been established previously in these animals. Two animals in the Tu-177 group had complete clinical and pathological regression of their established s.c. tumor nodule. Two animals in the Tu-138 group were killed early because they were experiencing rapid growth and ulceration of the control tumor sites. All surgical sites had developed lesions of at least 6 mm$^3$ before intervention. The tumor volumes on necropsy are shown in Table 1.

Discussion

Mutations or deletions of the p53 tumor suppressor gene are the most frequent genetic alterations reported in SCCHN. Since the wild-type p53 gene is believed to be involved primarily in delivering antiproliferative signals that may be capable of antagonizing the growth-stimulatory signals propagated by oncogene products, the potential molecular therapeutic effect of this gene in SCCHN deserves attention.

The rapid development in the field of gene therapy, including the creation of adenoviral vectors, has created an environment that is well suited for progress toward novel gene therapy of SCCHN. Because of their natural tropism for aerodigestive tract epithelium, adenoviruses may be uniquely suitable for the transient delivery of genes to cancers in these epithelial tissues. The recombinant, replication-defective adenoviruses that have been developed for gene therapy are missing the entire E1a and part of the E1b regions and are, therefore, capable of propagating only in cells that can provide the E1 proteins in trans, such as the 293 cell line. In the past few years, recombinant adenoviruses have been extensively developed and used for in vivo gene therapy. The high transfer efficiency of adenoviral vectors over a broad range of hosts both in vitro and in vivo make them attractive vehicles for molecular therapy. Recently, a recombinant wild-type p53 adenoviral vector (Ad5CMV-p53) was generated. This provided us with an excellent candidate for investigation of the biological effects of the wild-type p53 gene product on SCCHN cells bearing the mutated p53 gene. Using a $\beta$-gal recombinant adenovirus, the gene transfer efficiency of SCCHN cells was established. Approximately 60% of SCCHN cells were positive after X-gal staining. There appeared to be a linear correlation between the number of cells expressing the gene and the amount of viral particles used in the experiment. This result coincided with the efficiency obtained in cells infected with Ad5CMV-p53 after immunostaining by using a monoclonal anti-p53 antibody. Our observed transduction efficiency was lower than that achieved in other cell lines tested, including HeLa, HepG2, Lm2, and the human non-small cell lung cancer cell lines. This discrepancy could be due to a host of factors, including receptor variations and differences in membrane characteristics among the cell lines. Additionally, the transduction efficiency of SCCHN cells may have been underestimated by limitations of light microscopic analyses.

Ad5CMV-p53 mediated a high level of expression of the p53 gene in SCCHN cells. Two p53 mRNA species were detected in the Ad5CMV-p53-infected cells. The high level of 1.9-kilobase mRNA was derived from the transduced p53 CDNA following infection with Ad5CMV-p53, indicating that the adenoviral vector is an efficient vehicle for gene delivery into human SCCHN cells. Moreover, the levels of endogenous 2.8-kilobase mRNA were higher in the transduced cells than in the controls, presumably due to the effect of wild-type p53 gene product. This phenomenon of transcriptional
GROWTH SUPPRESSION OF SCCHN BY ADENOVIRUS WILD-TYPE p53

autoregulation of the p53 gene has been well documented in murine cell lines in which the wild-type p53 can transactivate its own promoter and the mutant p53 fails to regulate the p53 promoter (24).

Due to the episomal property of adenoviral vectors, all the input DNA following infection with AdSCMV-p53 is presumably degraded slowly throughout incubation. By using polymerase chain reaction-based detection techniques, DNA can be detected as late as 14 days postinfection (data not shown).

Western blot analysis demonstrated that there were few or no changes of p53 protein levels between mock- and replication-defective adenovirus-infected cells, whereas production of p53 protein was significant in AdSCMV-p53-infected cells, suggesting that the exogenous p53 mRNA was efficiently translated. Time course protein expression studies have shown protein expression to peak 3 days postinfection and progressively decline to still detectable Western blotting levels on day 15 (22). Functionally, these SCCHN cells transduced with wild-type p53 gene exhibited significant inhibition of growth in vitro as compared to the mock-infected and replication-defective cells, thus clearly illustrating that these results were not mediated by the virus itself. The mechanism by which wild-type p53 protein inhibits growth in vitro may be related to arrest of the G1 cell cycle (18), apoptosis (19, 20), or induction of another tumor suppressor gene such as WAF1/CIP1 (25). The induction of apoptosis is one of the several documented functions of wild-type p53. When Tu-138 and Tu-177 cells were infected with AdSCMV-p53 at 100 plaque-forming units/cell, the characteristic apoptotic histomorphology, such as rounded-up cells and the formation of blebs, was apparent as early as 4 h after infection and was followed rapidly by cell death (data not shown). However, the mechanism of growth suppression and cell death induced by AdSCMV-p53 requires further investigation.

Encouraging results were also obtained in the nude mouse studies. Tumor growth in the AdSCMV-p53-infected cells was suppressed by at least 60 times more than in the experimental controls. These in vivo results confirmed the in vitro effects of AdSCMV-p53 on human SCCHN cells, suggesting that the wild-type p53 protein mediates a potentially therapeutic effect. Although the in vivo studies are in their infancy, they nevertheless portend the development of a model for gene therapy in SCCHN that uses p53 adenovirus as a therapeutic intervention. Information derived from such studies could be expanded in the development of other novel molecular therapies that use adenoviral vectors, not only in SCCHN but in other human cancers. Several critical questions remain unanswered. How should the insult from antibodies that may arise in animals or patients following viral treatment be alleviated? How safe is this virus in humans? The results of the preliminary studies justify further investigation of in vivo animal models as well as mechanisms through which wild-type p53 regulates these in vitro and in vivo effects.

References


Growth Suppression of Human Head and Neck Cancer Cells by the Introduction of a Wild-Type \textit{p53} Gene via a Recombinant Adenovirus

Ta-Jen Liu, Wei-Wei Zhang, Dorothy L. Taylor, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/54/14/3662

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.